Replies to post #139875 on Biotech Values

[DewDiligence]

SPPI—I don't expect AGN to continue to pursue apaziquone with SPPI in future trials…

Agreed—continuing its involvement after a phase-3 failure (despite the purportedly favorable pooled data) would be contrary to AGN’s corporate M.O.